Elosulfase alfa

Drug Profile

Elosulfase alfa

Alternative Names: BMN-110; GALNS; Recombinant N-acetylgalactosamine-6-sulfatase; rhGALNS; Vimizim

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Chondroitinsulfatases; Recombinant proteins
  • Mechanism of Action GALNS protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis IV
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis IV

Most Recent Events

  • 01 Dec 2016 BioMarin completes a phase III extension trial for Mucopolysaccharidosis IV in USA, Argentina, Brazil, Canada, Denmark, France, Germany, Italy, Japan, South Korea, Netherlands, Norway, Colombia, Portugal, Qatar, Saudi Arabia, Spain, Taiwan and United Kingdom (NCT01415427)
  • 21 Jul 2016 Biomarkers information updated
  • 01 Jun 2016 BioMarin Pharmaceutical completes a phase II trial for Mucopolysaccharidosis IV in children under 5 years of age in USA, Italy, Taiwan and United Kingdom (NCT01515956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top